Advances in Clinical Chemistry

Advancements in Clinical Chemistry, Volume 106, covers the latest technologies in clinical chemistry, including ADAMTS biomarkers, fibrosis biomarkers, metabolomics, long non-coding RNAS, myostatin, and metadherin.

Format: Hardback
Length: 298 pages
Publication date: 20 January 2022
Publisher: Elsevier Science & Technology

The 106th volume of Advances in Clinical Chemistry, an esteemed series recognized globally, presents a collection of chapters authored by esteemed clinical laboratory scientists, physicians, and research scientists. This serial delves into the forefront of clinical chemistry, exploring the latest and most cutting-edge technologies in the field. In this latest release, the focus is on significant advancements in ADAMTS biomarkers, fibrosis biomarkers in nonalcoholic fatty liver disease, metabolomics of peripheral artery disease, molecular and cellular functions of long non-coding RNAS in prostate and breast cancer, myostatin: basic biology to clinical application, and metadherin (AEG-1/MTDH/LYRIC) expression: significance in malignancy and its crucial role in colorectal cancer.

ADAMTS biomarkers have gained significant attention in recent years due to their potential in diagnosing and monitoring various cardiovascular diseases. This volume highlights recent developments in the field, including the use of novel biomarkers, such as TIMP-2 and TGF-β1, for the early detection and risk assessment of cardiovascular events. The chapter on Advances in fibrosis biomarkers in nonalcoholic fatty liver disease explores the role of these biomarkers in predicting disease progression, monitoring treatment response, and identifying novel therapeutic targets.

Metabolomics, a powerful tool for analyzing complex biological samples, has been extensively used in the study of peripheral artery disease. This volume presents comprehensive reviews on the use of metabolomics to identify biomarkers of disease risk, predict disease outcomes, and develop personalized treatment strategies. The chapter on Molecular and cellular functions of long non-coding RNAS in prostate and breast cancer explores the role of these non-coding RNAs in regulating gene expression and their potential as biomarkers and therapeutic targets in these cancers.

Myostatin, a growth hormone-inhibiting protein, has been implicated in various human diseases, including muscle wasting, osteoporosis, and cancer. This volume presents a comprehensive review on the basic biology of myostatin and its clinical applications, including the development of myostatin inhibitors as potential therapeutics for these diseases. The chapter on Metadherin (AEG-1/MTDH/LYRIC) expression: Significance in malignancy and crucial role in colorectal cancer explores the expression of metadherin in cancer and its role in promoting tumor growth, metastasis, and resistance to chemotherapy.

In conclusion, Advances in Clinical Chemistry, Volume 106, serves as a valuable resource for clinical laboratory scientists, physicians, and researchers interested in the latest advancements in clinical chemistry. The chapters presented in this volume cover a wide range of topics, from ADAMTS biomarkers to metabolomics, and provide insights into the potential applications of these technologies in diagnosing, treating, and managing various diseases.

Weight: 450g
Dimension: 229 x 152 (mm)
ISBN-13: 9780323988377